Our Approach

Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (acquired by Pfizer) to advance a portfolio of centrally-acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). GPCRs have been proven to be the most successful class of druggable targets in the human genome and make up 50-60% of all druggable targets in the body.  Longboard’s small molecule product candidates were discovered out of the same world-class GPCR research platform at Arena that represents a culmination of more than 20 years of drug development and optimization.

Our Pipeline

GPCRs are highly validated therapeutic targets.

G protein-coupled receptors
(GPCRs) represent
50 – 60%
of druggable targets in body
GPCRs are the largest and most diverse protein family, corresponding to
2%
of the human genome
GPCRs represent
40%
of prescription drugs

AT LONGBOARD, WE ARE DEVELOPING THE NEXT GENERATION OF THIS PROVEN CLASS OF DRUGS

Our therapeutic candidates are designed with the selectivity and specificity of next generation therapies that may translate into favorable profiles and potentially improved safety.

Therapeutic Areas of Interest

There are multiple Developmental and Epileptic Encephalopathy (DEE) syndromes affecting infants, children and adults across the world, and there is a significant unmet need for treating and controlling multiple different seizure types across these populations. Learn more here.

DEEs refer to a group of severe heterogeneous epilepsies that are characterized by drug resistant seizures and significant developmental delay.

Importantly, if seizure control can be improved, developmental delay may slow. Most DEEs begin early in life, often starting in infancy. Children can have frequent and severe seizures which may be of multiple types. Epileptic spasms, tonic or atonic seizures and myoclonic seizures, among other seizure types, can be seen. In many cases, seizures are life long, although in some instances they can abate with time with certain syndromes or specific causes. Learn more.

Dravet syndrome, also known as Severe Myoclonic Epilepsy of Infancy (SMEI), is a rare form of drug-resistant epilepsy that begins in infancy and proceeds with accumulating morbidity that significantly impacts individuals throughout their lifetime. Approximately 80-85% of Dravet patients have a mutation in their SCN1A gene. Learn more.

LGS is a developmental brain disorder that frequently evolves from early-life-onset epilepsy with multiple different types of seizures. Abnormal brain waves seen in LGS helps physicians examine brain structure and potentially locate the cause of the seizure activity. Because the seizures associated with LGS are usually resistant to treatment, intellectual impairment and learning problems may worsen over time. Learn more.

TSC is a genetic disorder that causes tumors to form in many different organs, primarily in the brain, eyes, heart, kidney, skin and lungs. The aspects of TSC that most strongly impact quality of life are generally associated with the brain: seizures, developmental delay, intellectual disability and autism. Learn more.

CDD is a rare developmental epileptic encephalopathy caused by mutations in the CDKL5 gene, and this can manifest in a broad range of clinical symptoms and severity. The hallmarks are early-onset, intractable epilepsy and neurodevelopmental disability impacting cognitive, motor, speech, and visual function. Although rare, it is one of the most common forms of genetic epilepsy. Learn more.

Publications

Longboard Pharmaceuticals – Corporate Overview

ILAE’s 15th Annual European Epilepsy Congress (EEC) – September 7-11, 2024 – Rome, Italy

Safety and Tolerability of Bexicaserin in Adolescents and Adults with Developmental and Epileptic Encephalopathies: Interim Results of the Phase 1b/2a PACIFIC Study Open-Label Extension (OLE) – LATE BREAKER
Dewey McLin, Chad Orevillo, Minh Le, Randall Kaye

Bexicaserin has Negligible CYP Or P-glycoprotein Interaction Potential, Minimizing Therapeutic Complexity In Epilepsy Patients with a High Burden of Polypharmacy
Rosa Chan, Nuggehally Srinivas, Anne Danks, Chad Orevillo, Dewey McLin, Randall Kaye

A Phase 1 Study Of 5-HT2C Superagonist LP352 Shows Robust Brain Penetration, a Strong Correlation Between Plasma and CSF Pharmacokinetics and QEEG Changes Reflecting Receptor Engagement
Nuggehally Srinivas, David Vossler, Rosa Chan, Dewey McLin, Chad Orevillo, Randall Kaye

Bexicaserin, A 5-HT2C Superagonist, has Broad Antiepileptic Activity in Preclinical Seizure Models
Anne M. Danks, Marco Peters, Randall Kaye

Academy of Neurology (AAN) Annual Meeting – April 13-18, 2024 – Denver, Colorado

Efficacy And Safety Of Bexicaserin (LP352) In Adolescent And Adult Participants With Developmental And Epileptic Encephalopathies: Results Of The Phase 1b/2a Pacific Study
Randall Kaye, Chad Orevillo, Dennis J. Dlugos, Ingrid E. Scheffer

AES Annual Meeting – December 1-5, 2023

Alternate Dosing Regimens for an Immediate Release Formulation of the Novel Antiseizure Medication LP352 Based on Pharmacokinetics (Plasma and CSF) and Pharmacodynamics (QEEG)
Randall Kaye, Nuggehally Srinivas, Dewey McLin, Chad Orevillo, David Vossler, Rosa Chan

LP352 has Negligible CYP or P-glycoprotein Interaction Potential, Minimizing Therapeutic Complexity in Epilepsy Patients With a High Burden of Polypharmacy
Rosa Chan, Nuggehally Srinivas, Anne Danks, Chad Orevillo, Dewey McLin, Randall Kaye

LP352, a 5-HT2C Superagonist, Has Broad Antiepileptic Activity in Preclinical Seizure Models
Anne M. Danks, Marco Peters, Randall Kaye

ACCP September 10-12, 2023 – Bellevue, WA

A Phase 1 Study of 5-HT2C Superagonist LP352 Shows Robust Brain Penetration, a Strong Correlation Between Plasma and CSF Pharmacokinetics, and QEEG Changes Reflecting Receptor Engagement
Nuggehally Srinivas, David Vossler, Rosa Chan, Dewey McLin, Chad Orevillo, Randall Kaye

IEC September 2-6, 2023 – Dublin, Ireland

A Phase 1 Clinical Study Shows Robust LP352 CSF Exposures Supporting Dose Optimization for 5-HT2C Receptor Engagement
Nuggehally Srinivas, Rosa Chan, Dewey McLin, Chad Orevillo, Gale O’Connell, Randall Kaye

The PACIFIC Study: A Phase 1b/2a Study to Investigate the Safety, Tolerability, Pharmacology, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies
Chad Orevillo, Sandy Bialek, Dennis Dlugos, Jacqueline French, Randall Kaye

Searching for Safer and More Effective Medications in the Management of Seizure Disorders: A 5-HT2C Superagonist
Randall Kaye, Graeme Semple, David Unett, Ibragim Gaidarov, Todd Anthony

Evaluation of Prolactin as a Useful Pharmacodynamic Tool to Assess Engagement of Central 5-HT2C Receptors by LP352, a Potent and Selective 5-HT2C Agonist
Rosa Chan, Dewey McLin, Randall Kaye

American Epilepsy Society (AES) 2022 Annual Meeting

Evaluation of Prolactin as a Useful Pharmacodynamic Tool to Assess Engagement of Central 5-HT2C Receptors by LP352, a Potent and Selective 5-HT2C Agonist
Rosa Chan, Dewey McLin, Randall Kaye

Searching for Safer and More Effective Medications in the Management of Seizure Disorders: A 5-HT2C Superagonist
Randall Kaye, Graeme Semple, David Unett, Ibragim Gaidarov, Todd Anthonye

American Academy of Neurology (AAN) Annual Meeting 2022

Single Ascending Dose Pharmacokinetics (PK), Pharmacodynamics (PD), and Tolerability of LP352 in Healthy Subjects
Dolly A. Parasrampuria, Ian Mills, Gale O’Connell, Archana Chaudhary, Jon Ruckle, Chad Orevillo, Phil Perera

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Pharmacokinetics (PK), Pharmacodynamics (PD), and Tolerability Study of LP352 in Healthy Subjects
Dolly A. Parasrampuria, Ian Mills, Gale O’Connell, Archana Chaudhary, Jon Ruckle, Chad Orevillo, Phil Perera

Live the
Longboard Life.

We are committed to improving the quality of life for individuals with devastating neurological conditions and strive to be the best possible teammates and colleagues. Learn more about our culture, benefits and open positions.

We show up
for patients.

The people living with, supporting and treating those with neurological conditions are at the center of what we do. Learn more about our commitment.